Etelcalcetide is a synthetic peptide calcimimetic, and one of a small number of peptides in this reference with a UK marketing authorisation rather than a grey-market listing. Licensed across the EU, and therefore in the UK, as Parsabiv, it is indicated for secondary hyperparathyroidism in adults with chronic kidney disease who are on haemodialysis. Its evidentiary position is unusual for a peptide: it is a prescription-only medicine with a NICE technology appraisal, not a research-use-only product.
What etelcalcetide is
Etelcalcetide is an intravenously administered synthetic peptide. It acts as a positive allosteric modulator of the calcium-sensing receptor (CaSR) on parathyroid chief cells: it binds the receptor's extracellular domain and increases the receptor's sensitivity to extracellular calcium, which in turn reduces parathyroid hormone (PTH) secretion. Because it is given intravenously during dialysis, it is administered by clinicians in a supervised hospital setting rather than by patients at home.
One receptor, two binding sites
Etelcalcetide is usually described alongside cinacalcet, the older oral calcimimetic. The two differ in chemistry and in where they bind. Cinacalcet is a small molecule that binds within the seven-transmembrane domain of the CaSR; etelcalcetide is a peptide that binds the extracellular N-terminal domain. Different binding sites converge on the same physiological effect: a downward shift in the calcium concentration needed to activate the receptor, and a fall in PTH. It is a clean illustration of how a peptide and a small molecule can target one receptor by different routes.
What the trial evidence shows
In a randomised Phase 3 trial in patients receiving haemodialysis with secondary hyperparathyroidism, etelcalcetide was shown to be non-inferior to cinacalcet for lowering PTH over the study period (Block et al., JAMA 2017). The Scottish Medicines Consortium, reviewing the same evidence, summarised it as at least as effective as another calcimimetic in reducing parathyroid hormone levels. The evidence base is human, randomised and substantial — a contrast with most research peptides, whose human record is thin and often uncontrolled.
UK licensing and funding
Etelcalcetide holds an EU marketing authorisation (EU/1/16/1142), on which UK supply has rested; it is a prescription-only medicine and is subject to additional monitoring (the black-triangle symbol). NICE technology appraisal TA448 (2017) recommends etelcalcetide as an option for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis, within defined criteria, and NHS England commissions it accordingly; local formularies typically restrict initiation to specialist clinicians. Scotland diverges: the Scottish Medicines Consortium (advice 1262/17, published 11 September 2017) did not recommend etelcalcetide for use within NHS Scotland, on the grounds that the submitting company did not present a sufficiently robust economic analysis. The same medicine therefore sits differently in each UK nation — a reminder that a marketing authorisation and an NHS funding decision are separate steps.
Safety and immunogenicity
As with any peptide, immunogenicity is a theoretical concern. In clinical trials of patients treated for up to six months, 7.1% tested positive for binding anti-etelcalcetide antibodies; there was no evidence of altered pharmacokinetics, clinical response or safety associated with those antibodies. The most prominent effect in trials was a fall in blood calcium (hypocalcaemia), and the product information contraindicates starting treatment where corrected serum calcium is below the lower limit of the normal range. These are clinical-management facts, reported here as research findings and regulator labelling, not as guidance for personal use.
How this grades
The peptide field's human-data ceiling keeps most compounds at Limited. Etelcalcetide is the exception that tests the rule: a licensed medicine with randomised Phase 3 data and a NICE recommendation. Peptide Data grades it Moderate to Strong, and states plainly that the grade derives from the licensed clinical literature rather than from the grey-market research pool.
Research-use-only
This article describes a prescription-only medicine licensed for a specific clinical indication. Peptide Data does not provide dosing, administration or consumption advice for any compound, and nothing here should be read as advocating personal use. Research-use-only framing holds throughout: the mechanism, trials and regulatory position are described, never recommended.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.